577 | Table 1 Lifespan analyses frh-1 dsRNA constructs - summary statistics | ✘ | — | WT | RNA Interference | frh-1 IV(RNAi) | — | — | 20.9 | — | 37.0 | 149 |
576 | Table 1 Lifespan analyses frh-1 dsRNA constructs - summary statistics | ✘ | — | WT | RNA Interference | frh-1 III(RNAi) | — | — | 16.7 | — | 27.0 | 130 |
575 | Table 1 Lifespan analyses frh-1 dsRNA constructs - summary statistics | ✘ | — | WT | RNA Interference | frh-1 II(RNAi) | — | — | 17.2 | — | 27.0 | 140 |
574 | Table 1 Lifespan analyses frh-1 dsRNA constructs - summary statistics | ✘ | — | WT | RNA Interference | frh-1 I(RNAi) | — | — | 18.3 | — | 27.0 | 130 |
573 | Table 1 Lifespan analyses frh-1 dsRNA constructs - summary statistics | ✔ | — | WT | Mutation | — | — | — | 17.6 | — | 27.0 | — |
565 | Figure 3 Increased BubR1 expression protects against spontaneous tumours and extends lifespan | ✘ | — | T23 | — | — | — | — | — | — | 1058.0 | 57 |
564 | Figure 3 Increased BubR1 expression protects against spontaneous tumours and extends lifespan | ✔ | — | T-GFP | — | — | — | — | — | — | 882.0 | 36 |
563 | Figure 3 Increased BubR1 expression protects against spontaneous tumours and extends lifespan | ✘ | — | T23 | — | — | — | — | — | — | 1058.0 | 57 |
562 | Figure 3 Increased BubR1 expression protects against spontaneous tumours and extends lifespan | ✘ | — | T-GFP | — | — | — | — | — | — | 882.0 | 36 |
561 | Figure 3 Increased BubR1 expression protects against spontaneous tumours and extends lifespan | ✔ | — | WT | — | — | — | — | — | — | 1250.0 | 60 |
560 | Figure S3 Overall and tumor-free survival of T23 animals is extended in females | ✘ | — | T23 | — | — | — | — | — | — | 1003.0 | 28 |
559 | Figure S3 Overall and tumor-free survival of T23 animals is extended in females | ✔ | — | T-GFP | — | — | — | — | — | — | 803.0 | 14 |
558 | Figure S3 Overall and tumor-free survival of T23 animals is extended in females | ✘ | — | T23 | — | — | — | — | — | — | 1003.0 | 28 |
557 | Figure S3 Overall and tumor-free survival of T23 animals is extended in females | ✘ | — | T-GFP | — | — | — | — | — | — | 803.0 | 14 |
556 | Figure S3 Overall and tumor-free survival of T23 animals is extended in females | ✔ | — | WT | — | — | — | — | — | — | 1057.0 | 30 |
555 | Figure S3 Overall and tumor-free survival of T23 animals is extended in males | ✘ | — | T23 | — | — | — | — | — | — | 1246.0 | 29 |
554 | Figure S3 Overall and tumor-free survival of T23 animals is extended in males | ✔ | — | T-GFP | — | — | — | — | — | — | 882.0 | 22 |
553 | Figure S3 Overall and tumor-free survival of T23 animals is extended in males | ✘ | — | T23 | — | — | — | — | — | — | 1246.0 | 29 |
552 | Figure S3 Overall and tumor-free survival of T23 animals is extended in males | ✘ | — | T-GFP | — | — | — | — | — | — | 882.0 | 22 |
551 | Figure S3 Overall and tumor-free survival of T23 animals is extended in males | ✔ | — | WT | — | — | — | — | — | — | 999.0 | 30 |
531 | Table 3 Parameters of life span in female SHR mice treated and not treated with metformin | ✘ | — | — | Mutation | — | — | — | 535.0 | 570.0 | 898.0 | 50 |
530 | Table 3 Parameters of life span in female SHR mice treated and not treated with metformin | ✔ | — | — | Mutation | — | — | — | 388.0 | 297.0 | 814.0 | 50 |
529 | Table 4 Effect of metformin on parameters of life span in female HER-2/neu mice | ✘ | — | — | Mutation | — | — | — | 285.0 | — | 340.0 | 32 |
528 | Table 4 Effect of metformin on parameters of life span in female HER-2/neu mice | ✔ | — | — | Mutation | — | — | — | 264.0 | — | 311.0 | 34 |
525 | Fig. 3. Animal survival and growth | ✘ | Wistar | — | Mutation | — | — | — | 62.0 | 42.0 | 66.0 | 6 |